A rough guide to…advisory boards
PMLive | March 23, 2016
Our intrepid writers take us on a journey through advisory boards and show that pre-trip planning is the pathway to perfection
Read more ›
Nine Key Elements to Ensure Advisory Board Success
PM360 | June 17, 2014
The relationship between pharmaceutical companies and medical stakeholders will need to evolve thanks to the greater public scrutiny these relationships will now receive under various regulatory changes including the Sunshine Act.
Getting the Right Relationship Between Doctors and Drug Companies
The Atlantic | May 7, 2013
There is a way to cultivate, not demonize, collaboration between physicians and pharma.
Pharma Medical Affairs: 2020 and Beyond
McKinsey & Company | 2014
Pharma’s Medical Affairs faces growing internal and external challenges as
well as new opportunities
Patients, Physicians, and Payers…How Can Pharma Do It All?
PharmaExec.com | March 18, 2015
The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric – combined, it’s counterintuitive…if not overwhelming.
Pharmaceutical companies should focus on medication adherence to improve revenue
Healthcare Finance Network | June 14, 2018
A more concerted effort by pharmaceutical companies to drive medication adherence could help them increase their sales growth and margin profile.
Doctors and pharmaceutical companies work together to improve patient care-not pad pockets | Opinion
Penn Live | August 22, 2018
In recent years there has been a push towards more transparency regarding the financial relationship between physicians and pharmaceutical companies.
An Unwarranted Attack on Rare Disease Research
Forbes | August 28, 2018
Is the FDA really “less fussy about the kind of data that it requires for approval of a new drug for a rare disease“?
Three Key Components of Multichannel Marketing to Healthcare Providers
Forbes | January 11, 2019
Impactful multichannel marketing (MCM) campaigns that take HCPs on relevant, personalized journeys are the cornerstone of this objective.
Big Pharma’s Drug Studies are Getting a NASA-Style Makeover
Bloomberg Businessweek | January 24, 2019
A third of development costs comes from clinical trials. Novartis wants to make them cheaper and faster.